Tenax Therapeutics, Inc.
TENXHealthcare|Biotechnology|US
$1.69
+0.06 (+3.68%)
DCF Value
$2.35
Tangible Book / Share
$2.03
Cash / Share
$2.13
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07288398 LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 | Pulmonary Hypertension Associated With HFpEF | P3 | Active | 540 | RCT, Double-blind | TNX-103, Placebo |
| NCT05983250 LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Pulmonary Hypertension | P3 | Active | 230 | RCT, Double-blind | TNX-103, Placebo |
| NCT02025621 Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass | Coronary Artery Bypass Grafting, Mitral Valve Surgery | P3 | Completed | 882 | RCT, Double-blind | Levosimendan, Placebo |
| NCT07436689 Long-Term Open-Label Extension Study of Oral Levosimendan | Pulmonary Hypertension Associated With HFpEF | P3 | By Invite | 800 | Open-label | TNX-103 |
| NCT00174980 Study of Oxycyte in Severe Closed Head Injury | Traumatic Brain Injury | P2 | Terminated | 9 | Open-label | Oxycyte |
| NCT03541603 Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF | Hypertension Pulmonary Secondary, Heart Failure, Right Sided | P2 | Completed | 44 | RCT, Double-blind | Levosimendan, Matching Placebo |
| NCT00908063 Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI) | Traumatic Brain Injury | P2 | Terminated | 18 | RCT, Double-blind | Oxycyte, Normal Saline |
| NCT03624010 Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients | Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction | P2 | Completed | 35 | Open-label | Levosimendan |
| NCT02973620 Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure | Heart Decompensation | NO_LONGER_AVAILABLE | — | — | Levosimendan |